look alive, it’s time to revive€¦ · presentation to the ed opioid shortages opioid epidemic...
Post on 27-Jul-2020
4 Views
Preview:
TRANSCRIPT
6/29/2018
1
Look Alive, It’s Time to ReviveLook Alive, It’s Time to ReviveRuben Santiago, Pharm.D., BCPS, BCCCPEmergency Medicine Clinical PharmacistJackson Memorial Hospital, Miami, FLAugust 3, 2018
#FSHP2018Disclosure
• I do not have a vested interest nor am I affiliated with any corporate organization offering financial support or grant monies for this continuing education activity, or have any affiliation with an organization whose philosophy could potentially bias my presentation
2
#FSHP2018
Pharmacist ObjectivesPharmacist Objectives• Discuss recent changes in law regarding naloxone
availability and use by non-medical personnel
• Review naloxone administration and dosing strategies
• Design a treatment algorithm for opioid overdose and identify appropriate use of naloxone that includes first responders and Emergency Medical Services
• Describe alternative pain management options in the emergency department to minimize opioid use
3
#FSHP2018
Technician ObjectivesTechnician Objectives
• Discuss recent changes in law regarding naloxone availability and use by non-medical personnel
• Review naloxone administration and dosing strategies
• Identify appropriate use of naloxone that includes first responders or Emergency Medical Services
• Describe alternative pain management options in the emergency department to minimize opioid use
4
#FSHP2018
5
Sobering Statistics
115 Americans die everyday from an opioid overdose
In 2016, 63,632 Americans died due to an overdose with ~2/3 involving an opioid
The number of deaths caused by overdose attributed to opioids is 5x higher in 2016 than it was in 1999
6
Understanding the Epidemic. CDC.gov. August 2017.U.S. drug overdose deaths continue to rise; increase fueled by synthetic opioids. CDC.gov. March 2018
6/29/2018
2
Prescription opiates in the
(1990s)
Illicitly Manufactured
Fentanyl (2013)
Heroin (2010)
7
Understanding the Epidemic. CDC.gov. August 2017.
8
“Lotta drug dealin’ ’round me goin’ down in Dade county”
- Rick Ross, “Hustlin’”
9
#FSHP2018
Opioid Epidemic in Florida
2016 •2,798 opioid related overdose deaths
1,566 •Synthetic opioid related deaths in 2016
2013 •200 synthetic opioid deaths
2015 •12.7 million prescriptions for opioids
10
National Institute on Drug Abuse. Florida Opioid Summary. February 2018.
Florida Laws
911 Good Samaritan Act
Emergency Treatment and Recovery Act
HB 1241 –Pharmacists sell
naloxone without a prescription
2012 2015 2016
11
#FSHP2018
2017: Florida State of Emergency
• Executive order 17-146: Opioid Epidemic Public Health Emergency
• Standing order for naloxone by State Surgeon General Dr. Celeste Philip
• Five essential steps for first responders by Substance Abuse and Mental Health Services Administration (SAMHSA)
#FSHP2018
12
6/29/2018
3
Florida Statute 381.887 – Emergency Treatment for Suspected Opioid Overdose• Caregivers• Emergency responders
• Law enforcement officers• Fire Fighters• Paramedics• Emergency medical technicians
• Crime laboratory personnel• Authorized health care practitioner
#FSHP2018
13
14
Classification of OpioidsPhenanthrenes
• Naturally occurring alkaloids: morphine, codeine
• Semi-synthetic: buprenorphine, butorphanol, hydrocodone, hydromorphone, nalbuphine, oxycodone, oxymorphone, heroin
Phenylpiperidines
• Synthetic: alfentanil, fentanyl, meperidine, sufentanil
Diphenylheptanes
• Synthetic: methadone
Trescot A, et. al. Pain Physician. 2008; 11: S133 – S153. Ch. 38: Opioids. Goldfrank’s Toxicologic Emergencies.
15
Pharmacology of Opioids
Mu
• Supraspinal analgesia, respiratory depression, euphoria, sedation, decreased gastrointestinal motility, physical dependence, pruritus, bradycardia
Kappa• Spinal analgesia, sedation, dyspnea, dependence, euphoria,
dysphoria, psychomimetic effects, respiratory depression, and miosis
Delta• Spinal analgesia, supraspinal analgesia, psychomimetic, and
dysphoric effects
Trescot A, et. al. Pain Physician. 2008; 11: S133 – S153.Ch. 38: Opioids. Goldfrank’s Toxicologic Emergencies.
16
#FSHP2018
17
Respiratory Depression
Central Nervous System Depression
Miosis Depression of Autonomic Activity
Opioid Toxidrome
Ruha A. Emerg Med Clin N Am. 2014; 32: 205–221.Levine M. CHEST. 2011; 140(3): 795 – 806.
18
#FSHP2018
6/29/2018
4
Naloxone (Narcan®)
Opioid antagonist
Initial dose: 0.4 – 2 mg
Onset:2 – 8 minutes
(varies)
Duration: 30 – 120 minutes (varies)
#FSHP2018
19
20
Intranasal (IN) Naloxone
Prevent needlestick injuries
Nasal cavity ideal for systemic drug absorption
Naloxone drug properties
#FSHP2018
21
Saved By the Nose – Denver Study
Design•Prospective evaluation of intranasal naloxone
Inclusion Criteria
•> 14 years of age •AMS, found down, suspected overdose
Protocol •IN naloxone via mucosal atomizer device, 1 mg per nare
Outcomes
•Patient response•Time to response post naloxone
Barton E. Journal of Emergency Medicine. 2005; 29(3): 265 – 271.
22
Results
• 95 patients• 52 responded to IN or IV
naloxone• 43/52 (83%) responded to
IN naloxone• 36/43 (84%) required no
further naloxone• 9/52 (17%) only responded
to IV naloxone0
2
4
6
8
10
12
Arrival to Clinical Response Drug Administration to ClinicalResponse
Min
utes
Response Times
IN Naloxone IV NaloxoneBarton E. J Emerg Med. 2005; 29(3): 265 – 271.
23
#FSHP2018
IV versus IN Naloxone Prehospital
Study Design
• Retrospective review March 2003 – July 2004
Inclusion criteria
• Patients transported by EMS for suspected narcotic overdose
Protocol
• IN naloxone 1 mg per nostril via MAD if suspected narcotic intoxication and respiratory depression
Outcomes
• Time from naloxone administration to clinical response, time from patient contact to clinical response
Robertson T. Prehospital Emergency Care. 2009; 13: 512 – 515.
24
#FSHP2018
6/29/2018
5
ResultsIV versus IN Naloxone as First-line Therapy (n = 154)
Outcomes IV Naloxone ( n = 104) IN Naloxone (n = 50)Positive Clinical Response* 58 (56%) 33 (66%)Drug to Clinical Response Time (minutes) 8.1 12.9
Patient Contact to Clinical Response Time (minutes) 20.7 20.3
Second Dose 19 (18%) 17 (34%)Rescue Dose 0 (0%) 3 (6%)
*Positive clinical response defined as increase in respiratory rate of at least 6 breaths per minute or improvement of Glasgow Coma Scale (GCS) of at least 6 points
Robertson T. Prehospital Emergency Care. 2009; 13: 512 – 515.
25
#FSHP2018
IM versus IN Naloxone
IM Naloxone 2 mg
Study Design: prospective, randomized,
unblinded trial
IN Naloxone 2 mg
Primary Outcome: proportion of patients with adequate response within 10 minutes
Kerr D. Addiction. 2009; 2067 – 2074.
26
#FSHP2018
Results
IM versus IN naloxone (n = 172) Outcomes IM naloxone (n = 89) IN naloxone (n = 83)Adequate response ≤ 10 minutes 69 (77.5%) 60 (72.3%)
Mean response time (minutes) 7.9 8
Rescue naloxone 4 (4.5%) 15 (18.1%)
Kerr D. Addiction. 2009; 2067 – 2074.
27
#FSHP2018
Nebulized Naloxone
Study Design• Convenience
sample of patients suspected of opioid intoxication
Objective• Describe
improvements in GCS and Richmond Agitation Sedation Scale (RASS) scores
Inclusion Criteria• > 18 years of age• No naloxone in the
prehospital setting• Received
nebulized naloxone for suspected opiate overdose
Protocol • > 6 breaths per
minute and suspected opioid intoxication
• 2 mg naloxone in 3 mL normal saline via nebulizer facemask
Baumann B. Am J Emerg Med. 2013; 585 – 588.
28
Results Nebulized
naloxone (n = 26)
11 patients received repeat
doses (IV, n = 2; IN, n = 1; nebulizer, n = 8)
• Median time to second dose 33 minutes (range 15 –300 minutes)
3 patients received repeat doses
(IV, n = 2; IN, n = 1)
• Time to third dose ranged from 30 – 224 minutes
Outcomes Pre-naloxone Post-naloxoneGCS
(median) 11 13
RASS (median) -3 -2
Baumann B. Am J Emerg Med. 2013; 585 – 588.
29 30
Overdose Prevention. Orange County Government Florida.
Accessed May 23, 2018.
6/29/2018
6
Five Essential Steps for First Responders
1. •Call 911
2. •Check for signs of opioid overdose
3. •Support the person’s breathing
4. •Administer naloxone
5. •Monitor the person’s response SAMHSA Opioid Overdose Prevention Toolkit: Five Essential Steps for First Responders. Revised 2016.
31
Executive Order Number 17-146Approved Options for Intranasal or Auto-Injector Administration
Intranasal Intranasal Auto-Injector
Naloxone 2 mg/2 mL prefilled syringe, # 2 syringesSIG: Spray one-half of the syringe into each nostril upon signs of opioid overdose.Call 911.May repeat x 1. Mucosal Atomization Device (MAD) # 2 SIG: Use as directed for naloxone administration. Kit must contain 2 prefilled syringes and 2 atomizers and instructions for administration.
Narcan Nasal Spray 4 mg, #2 SIG: Administer a single spray intranasally into one nostril. Call 911. Administer additional dose using a new nasal spray with each dose, if patient does not respond or responds and then relapses into respiratory depression. Additional doses may be given every 2 to 3 minutes until emergency medical assistance arrives.No kit is required.Product is commercially available.
Naloxone 0.4 mg/0.4 mL#1 twin packSIG: Use one auto-injector upon signs of opioid overdose. Call 911. May repeat x 1.Not kit is required.Product is commercially available.
Price: $135.99 Price: $4,500.00
32
Trends in Opioid Prescribing• 2010, enough opioids were
prescribed in the US that every American adult could be provided with 5 mg hydrocodone every 4 hours for a month
• More than 1 in every 6 patients discharged from an emergency department (ED) are given a prescription for an opioid pain reliever
• Survey of 59 patients in the ED who self-reported heroin, or non-medical opioid use (heroin use n = 42, heroin overdose n = 12, non-medical prescription opioid use n = 5)
• 35/59 (59%) of patients initial exposure to opioids legitimate prescription from a medical provider, 10 exposed in the ED
33
Butler M. Ann Emerg Med. 2016; 68(2): 202–208.
#FSHP2018
HB 21 signed into law March 19,
2018
> 16 years of age, a prescriber or dispenser must
consult E-FORSCE prior to prescribing
or dispensing a controlled substance
Prescription for a Schedule II opioid
for acute pain may not exceed a
3-day supply
7 – day supply of Schedule II opioid
may be prescribed for
certain indications
July 1, 2018
Scott, Jeff. Florida Medical Association.
34
Alternatives to Pain Management in the Emergency Department
Pain most common presentation to the
EDOpioid shortages Opioid epidemic
#FSHP2018
35
Non-Opioid Analgesics
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Acetaminophen
Nitrous Oxide
36
Motov S. J Emerg Med. 2018; 54(5): 731 – 736. Todd K. Pain Ther. 2017; 6: 193 – 202.
6/29/2018
7
Local and Regional Nerve Blocks
Headache Back pain
Hip fractures Trauma
37
Motov S. J Emerg Med. 2018; 54(5): 731 – 736. Todd K. Pain Ther. 2017; 6: 193 – 202.
Reisenauer S. Adv Emerg Nurs J. 2012. Roldan C. J Emerg Med. 2015; 49(6): 1004 – 1010.
#FSHP2018
KETAMINE
NMDA receptor antagonist
Decreases in acute pain, opioid tolerance, opioid-induced
hyperalgesia, allodynia, and neuropathic pain
SDDK potent analgesic and amnestic effects and
preserves airway reflexes, spontaneous respiration, and
cardiopulmonary stability
38
Ketamine for Acute Pain
Study Design
• Prospective, randomized, double-blind
Intervention
• 0.3 mg/kg ketamine versus 0.1 mg/kg morphine
Primary Outcome
• Pain reduction at 30 minutes
Patient Characteristics
• 18 – 55 years of age presenting to the ED for acute pain
Motov S. Ann Emerg Med. 2015; 66: 222 – 229.
39
#FSHP2018
ResultsKetamine versus Morphine for Acute Pain in
the ED (n = 90)
Time Interval
(minutes)
Ketamine (n = 45) Pain NRS (median)
Morphine (n = 45)Pain NRS (median)
Baseline 8.6 8.515 3.2 4.230 4.1 3.960 4.8 3.4
Motov S. Ann Emerg Med. 2015; 66: 222 – 229.
Adverse events higher at 15 minutes in the ketamine
group versus the morphine group
Adverse event reached equivalence at 30 minutes
No significant difference between groups in rescue medication at 30 minutes
40
#FSHP2018
Ketamine: To Push, or Not to Push?
Adverse effects, thought
to be attributable to
IV push administration
Prospective, randomized, double-blind,
double dummy
Ketamine 0.3 mg/kg given
IVP over versus short infusion
(SI) prepared in 100 mL of
normal saline over 15 minutes
Evaluated the overall rate as
well as the specific severity
levels of side effects
Motov S. Am J Emerg Med. 2017; 35: 1095 – 1100.
41
#FSHP2018
Results24 patients per group
Overall feeling of unreality was 91.7% in the IVP group vs. 54.2% in the SI group (p = 0.008)
Feeling of unreality score at five minutes: three for the IVP group versus zero for the SI group ( p = 0.001)
IVP group showed a significantly greater degree of sedation at five minutes (p = 0.01)
Start a DRIP, REDUCE the TRIP
Motov S. Am J Emerg Med. 2017; 35: 1095 – 1100.
42
6/29/2018
8
Lidocaine
Class 1b antiarrhythmic
Inhibits sodium channel
depolarization
Administered via various routes for
various pain syndromes
Complications -periorbital numbness,
dizziness, vertigo, dysarthria
43
Golzari S. Anesth Pain Med. 2014; 4(1): e15444.
#FSHP2018
Short half-life (60 – 120 minutes)
Analgesic, antihyperalgesic, anti-inflammatory
Predictable adverse effects
Studied for intravenous use for
pain in various settings
Lidocaine
Silva L. Ann Emerg Med. 2017. [Epub ahead of print].
44
Case Report 1 • 58 year old male • Acute pain
secondary to rotator cuff injury
• Unresponsive to opiates and NSAIDs
• Lidocaine 120 mg IV
• Discharged from ED
Case Report 2 • 29 year old male• Left flank pain• Previous Rx for
oxycodone/apap for renal colic
• Lidocaine 150 mg IV
• Discharged from ED
Case Report 3• 17 year old male• Traumatic ankle
injury • Persistent pain
despite morphine• Lidocaine 100 mg
IV• Discharged home
after orthopedic manipulation
Systematic Review• Assess safety and
efficacy of IV lidocaine for pain management in the ED
• ≥ 18 years of age who received IV lidocaine for pain
• Pain Presentations• Difference in
dosing strategies among studies
• Limited evidence
LIDOCAINE 45
Sin B. J Pharm Pract. 2017: 1 – 4. Sin B. Ann Pharmacother. 2016; 50(3): 242.
Wiafe J. Ann Pharmacother. 2017; 5(10): 923. Silva L. Ann Emerg Med.
2017. [Epub ahead of print].
Conclusion
• Opioid epidemic continues to plague the United States• Majority of fatal overdoses involve opiates• In Florida, first responders may administer naloxone for
reversal of opioid overdose• Expanding naloxone administration, in conjunction with
limiting number of days of opiate therapy, hope to decrease the number of opiate related adverse events
• Alternatives to opioids for pain management in the ED include sub-dissociative dose ketamine and lidocaine
46
#FSHP2018
47 References • Understanding the epidemic. Centers for Disease Control and Prevention. August 30, 2017.
https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed May 23, 2018. • U.S. drug overdose deaths continue to rise; increase fueled by synthetic opioids. Centers for Disease
Control and Prevention. March 29, 2018. https://www.cdc.gov/media/releases/2018/p0329-drug-overdose-deaths.html. Accessed May 23, 2018.
• Opioid-related overdose deaths. Florida Opioid Summary. National Institute on Drug Abuse. February 2018. https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/florida-opioid-summary. Accessed May 23, 2018.
• Florida Department of Health, Office of Communications. Gov. Scott Directs Statewide Public Health Emergency for Opioid Epidemic. Florida Health. May 3, 2017. http://www.floridahealth.gov/newsroom/2017/05/050317-health-emergency-opioid-epidemic.html. Accessed May 23, 2017.
• Chapter 38. Opioids. Goldfrank’s Toxicologic Emergencies. 8th ed. 2006. • Trescot A, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008; 11: S133 – S153.
48
#FSHP2018
6/29/2018
9
References • Ruha A, Levine M. Central nervous system toxicity. Emerg Med Clin N Am. 2014; 32: 205–221. • Levine M, Brooks D, Truitt C, et. al. Toxicology in the ICU – Part 1: general overview and approach to
treatment. CHEST. 2011; 140(3): 795 – 806. • Holstege C, Borek H. Toxidromes. Crit Care Clin. 2012; 28: 479 – 498. • Wermeling D. a response to the opioid overdose epidemic: naloxone nasal spray. Drug Deliv Transl Res.
2013; 3(1): 63–74. • Barton E, Colwell C, Wolfe T, et. al. Efficacy of intranasal naloxone as a needleless alternative for
treatment of opioid overdose in the prehospital setting. Journal of Emergency Medicine. 2005; 29(3): 265 – 271.
• Robertson T, Hendey G, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehospital Emergency Care. 2009; 13: 512 – 515.
• Kerr D, Kelly A, Dietze P, et. al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009; 2067 – 2074.
• Baumann B, Patterson R, Parone D, et. al. Use and efficacy of nebulized naloxone in patients with suspected opioid intoxication. Am J Emerg Med. 2013; 585 – 588.
49
#FSHP2018
References• Butler M, Ancona R, Beauchamp G. ED prescription opioids as an initial exposure preceding addiction.
Ann Emerg Med. 2016; 68(2): 202–208. • Scott, Jeff. Florida’s New Law on Controlled Substance Prescribing. Florida Medical Association. • Pourmand A, et. al. Low dose ketamine use in the emergency department, a new direction in pain
management. Am J Emerg Med. 2017; 35: 918 – 921. • Sin B, et. al. The use of subdissociative-dose ketamine for acute pain in the emergency department.
Academic Emergency Medicine. 2015; 22: 251 – 257. • Motov S, et. al. A prospective randomized, double-dummy trial comparing IV push low dose ketamine
to short infusion of low dose ketamine for treatment of pain in the ED. Am J Emerg Med. 2017; 35: 1095 – 1100.
• Motov S, et. al. Intravenous subdissociative-dose ketamine versus morphine for analgesia in the emergency department: a randomize controlled trial. Ann Emerg Med. 2015; 66: 222 – 229.
• Silva L, Scherber K, Cabrera D, et. al. Safety and efficacy of intravenous lidocaine for pain management in the emergency department: a systematic review. Ann Emerg Med. 2017. [Epub ahead of print].
• Golzari S, Soleimanpour H, Mahmoodpor A, Safari S, Ala A. Lidocaine and pain management in the emergency department: a review article. Anesth Pain Med. 2014; 4(1): e15444.
50
#FSHP2018
References • Wiafe J, Sin B. use of intravenous lidocaine for the treatment of acute pain in the emergency
department. Ann Pharmacother. 2017; 5(10): 923.• Sin B, Effendi M, Bjork C, Punnapuza S. The use of intravenous lidocaine for renal colic in the
emergency department. Ann Pharmacother. 2016; 50(3): 242.• Sin B, Gritsenko D, Tam G, Koop K, Mok E. The use of intravenous lidocaine for the management of
acute pain secondary to traumatic ankle injury: a case report. J Pharm Pract. 2017: 1 – 4. • Motov S, Strayer R, Hayes B, Reiter M, Rosenbaum S, Richman M, et. al. The treatment of acute pain in
the emergency department: a white paper position statement prepared for the American academy of emergency medicine. J Emerg Med. 2018; 54(5): 731 – 736.
• Todd K. A review of current and emerging approaches to pain management in the emergency department. Pain Ther. 2017; 6: 193 – 202.
• Reisenauer S. A needle in the neck – trigger point injections as headache management in the emergency department. Adv Emerg Nurs J. 2012; 34(4): 350 – 356.
• Roldan C, Hu N. Myofasical pain syndromes in the emergency department: what are we missing? J Emerg Med. 2015; 49(6): 1004 – 1010.
• Nejat A, Teymourian H, Behrooz L, Mosheni G. Pain management via ultrasound guided nerve block in emergency department; a case series study. Emergency. 2017; 5(1): e12.
51
#FSHP2018
Look Alive, It’s Time to ReviveLook Alive, It’s Time to ReviveRuben Santiago, Pharm.D., BCPS, BCCCPEmergency Medicine Clinical PharmacistJackson Memorial Hospital, Miami, FLAugust 3, 2018
#FSHP2018
top related